Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Infanrix hexa vs Infanrix-IPV/Hib + HBV in Infants
NCT01457495Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 1998
- Primary completion
- Sep 1999
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, open-label trial of pertussis filamentous haemagglutinin in hepatitis B (HBV), diphtheria, Haemophilus influenzae type b infection (Hib) and 3 more (2 arms), sponsored by GSK. Primary endpoint: Number of subjects with antibody titers equal to or greater than cut-off value at Month 3. Started Sep 1998; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
hepatitis B (HBV)diphtheriaHaemophilus influenzae type b infection (Hib)poliomyelitispertussis
Beyond the preview
Go deeper on NCT01457495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457495.